Skip to main content
. 2020 Nov 23;124(4):786–796. doi: 10.1038/s41416-020-01168-x

Table 3.

Disease-free survival in the TransSCOT cohort and associations of clinicopathological features with GMS (n = 2912).

Clinicopathological characteristics Disease-free survival GMS category
N (%)a Univariate HR (95% CI) P Multivariate HR (95% CI) P 0 (n = 383)
N (%)a
1 (n = 1867)
N (%)
2 (n = 663)
N (%)
Pearson X2
Gender
 Female 1135 (39) 156 (41) 716 (38) 263 (40) 0.63
 Male 1778 (61) 0.96 (0.83–1.11) 0.60 227 (59) 1151 (62) 400 (60)
T-stage
 T1 78 (3) 19 (5) 55 (3) 4 (1) <0.001
 T2 250 (9) 59 (15) 160 (9) 31 (5)
 T3 1696 (58) 227 (60) 1131 (61) 338 (51)
 T4 889 (30) 1.70 (1.51–1.91) <0.001 1.74 (1.53–1.98) <0.001 78 (20) 521 (28) 290 (43)
N-stage
 N0 556 (19) 79 (21) 362 (19) 115 (17) 0.002
 N1 1663 (57) 224 (58) 1086 (58) 353 (53)
 N2 694 (24) 1.75 (1.57–1.96) <0.001 1.73 (1.48–2.03) <0.001 80 (21) 419 (22) 195 (29)
Site
 Colon 2402 (82) 310 (81) 1522 (81) 570 (86) 0.021
 Rectum 511 (18) 0.69 (0.56–0.85) <0.001 0.12 73 (19) 345 (19) 93 (14)
Risk group
 T1-3/N1 (lower risk) 1284 (55) 202 (66) 861 (57) 221 (40) <0.001
 T4 and/or N2 (higher risk) 1073 (45) 2.45 (2.08–2.88) <0.001 0.13 102 (34) 644 (43) 327 (60)
Adjuvant therapy
 FOLFOX 846 (29) 120 (31) 526 (28) 200 (30) 0.36
 CAPOX 2067 (71) 1.08 (0.92–1.27) 0.32 263 (69) 1341 (72) 463 (70)
Treatment time
 3 months 1469 (50) 194 (51) 956 (51) 319 (48) 0.39
 6 months 1444 (50) 1.01 (0.88–1.16) 0.85 180 (49) 911 (49) 344 (52)
GMS
 0 300 (35)
 1 424 (49)
 2 138 (16) 1.48 (1.32–1.68) <0.001 1.28 (1.12–1.47) <0.001

aPercentages rounded to nearest whole number and may not total 100%.

Emboldened values indicates p value < 0.05